This variation in TP53 was encountered in more than 65% of the tumor tissue samples and was selected for validation using the SNP genotyping assay in a second cohort of matched lung cancer patients, but was not properly validated in the second cohort, as it was detected in only 11% of the analyzed samples. This evidence concerns the gene TP53 and neoplasm.